Crescendo Biologics appoints Dr Barbara Fleck as head of intellectual property
Drug discovery and developer Crescendo Biologics has appointed Dr Barbara Fleck as head of intellectual property.
Barbara Fleck, a European and chartered patent attorney, has over 13 years’ experience of intellectual property issues in the bio-therapeutics field, including four years as a partner at Marks&Clerk LLP.
The company says the appointment of Dr Fleck "ensures that Crescendo is maximising its IP position and potential for its Humabody products."
Dr Peter Pack, chief executive of Crescendo Biologics, says: “Barbara’s appointment means that Crescendo now has a dedicated IP expert for its rapidly growing portfolio of Humabody therapeutics. She brings a unique combination of experience in the biopharmaceutical industry, especially in the antibody field, ranging from patent portfolio development and management to prosecution and due diligence. As part of the management team, Barbara will provide invaluable senior level counsel on our IP strategy.”
While Dr Fleck herself adds: "Crescendo is transitioning to a product-oriented oncology therapeutics company. Having worked as an external advisor with Crescendo for the last six years, I am now very pleased to join the company’s senior leadership team at this pivotal time to ensure that Crescendo’s IP position remains strong.”
This announcement follows the appointment of antibody veteran Kevin Johnson as Chairman at the end of 2015.